{
    "clinical_study": {
        "@rank": "63781", 
        "arm_group": [
            {
                "arm_group_label": "Coating A", 
                "arm_group_type": "Experimental", 
                "description": "Each subject will in random order be allocated to three single-dose administrations of insulin 338 in a GIPET\u00ae I tablet with 3 different coatings, respectively, on three separate dosing visits (Visits 2, 3 and 4). Each of the three dosing days will be separated by a 3-week wash-out period (ranging from 20 to 28 days)"
            }, 
            {
                "arm_group_label": "Coating B", 
                "arm_group_type": "Experimental", 
                "description": "Each subject will in random order be allocated to three single-dose administrations of insulin 338 in a GIPET\u00ae I tablet with 3 different coatings, respectively, on three separate dosing visits (Visits 2, 3 and 4). Each of the three dosing days will be separated by a 3-week wash-out period (ranging from 20 to 28 days)"
            }, 
            {
                "arm_group_label": "Coating C", 
                "arm_group_type": "Experimental", 
                "description": "Each subject will in random order be allocated to three single-dose administrations of insulin 338 in a GIPET\u00ae I tablet with 3 different coatings, respectively, on three separate dosing visits (Visits 2, 3 and 4). Each of the three dosing days will be separated by a 3-week wash-out period (ranging from 20 to 28 days)"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of the trial is to investigate the\n      pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the\n      effect of the investigated drug on the body) of NNC0123-0000-0338 (insulin 338) in a tablet\n      formulation with three different coatings in healthy subjects."
        }, 
        "brief_title": "A Trial Investigating the Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in a Tablet Formulation With Three Different Coatings in Healthy Subjects", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetes", 
            "Healthy"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Body mass index 18.0-28.0 kg/m^2 (both inclusive)\n\n          -  Subject who is considered to be generally healthy based on the medical history,\n             physical examination, and the results of vital signs, ECG (electrocardiogram) and\n             clinical laboratory tests performed during the screening visit, as judged by the\n             investigator\n\n        Exclusion Criteria:\n\n          -  Known or suspected hypersensitivity to trial products or related products\n\n          -  Previous participation in this trial. Participation is defined as informed consent\n\n          -  Presence of clinically significant acute gastro-intestinal symptoms (e.g. nausea,\n             vomiting, heartburn or diarrhoea) within 2 weeks prior to first dosing, as judged by\n             the investigator"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01931137", 
            "org_study_id": "NN1953-3973", 
            "secondary_id": [
                "2012-004202-10", 
                "U1111-1134-6321"
            ]
        }, 
        "intervention": {
            "arm_group_label": [
                "Coating A", 
                "Coating B", 
                "Coating C"
            ], 
            "description": "Dose level of 8100 nmol will be orally administered as one tablet per dose.", 
            "intervention_name": "insulin 338 (GIPET I)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Insulin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 3, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Neuss", 
                    "country": "Germany", 
                    "zip": "41460"
                }
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Trial Investigating the Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in a Tablet Formulation With Three Different Coatings in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Area under the serum insulin 338 concentration-time curve", 
            "safety_issue": "No", 
            "time_frame": "From dosing to infinity calculated from a 0-288 hours NNC0123-0000-0338 serum concentration-time-curve based on 38 sampling time points."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01931137"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area under the serum insulin 338 concentration-time curve", 
                "safety_issue": "No", 
                "time_frame": "From 0 to 288 hours after a single dose (SD)"
            }, 
            {
                "measure": "Area under the glucose infusion rate (GIR)-time curve", 
                "safety_issue": "No", 
                "time_frame": "From 0 to 24 hours after a single dose"
            }, 
            {
                "measure": "Number of treatment emergent adverse events", 
                "safety_issue": "No", 
                "time_frame": "As recorded from trial product administration (Day 1) at Sub-visit A and until Sub-visit G (Day 13)"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}